Biotech



BlueOcean Nutraceuticals Inc.
Latest Comments
image_pdfimage_print
 

Scythian CEO on the potential impact of cannabinoid drugs on traumatic brain injuries


August 29, 2017
| August 29, 2017 | 1 Comment

Jonathan Gilbert, CEO and Director, and David Schrader, COO of Scythian Biosciences Corp. (TSXV: SCYB) (“Scythian”) in an interview with […]


Scythian to treat the secondary effects of traumatic brain injuries with cannabinoids


August 14, 2017
| August 14, 2017 | 3 Comments

Scythian BioSciences Corp. (TSXV: SCYB), which began trading on the TSXV last week under the symbol SCYB, is developing cannabinoid-based drugs to […]


BlueOcean’s Pure Polar on its way to Europe


June 21, 2017
| June 21, 2017

BlueOcean NutraSciences Inc. (TSXV: BOC) (“BlueOcean”) announced that it has received its first order from a distributor in the European Union […]


IntelGenX on the way to take some of the $16bn thin films market


June 08, 2017
| June 08, 2017

As a technophile, IntelGenX Technologies Corp. (TSXV: IGX | OTCQX: IGXT) (“IntelGenX”) have always intrigued me. The company developed a […]


Commercialising graphene: Graphene oxide biosensors


April 24, 2017
| April 24, 2017 | 3 Comments

What is a biosensor? Ladies, bear with me for a minute. Prostate cancer is the most common cancer in men […]


 

BlueOcean’s founder on astaxanthin – the “next wonder antioxidant”


March 14, 2017
| March 14, 2017 | 1 Comment

Sam Kanes, VP of Strategy and Investor Relations for BlueOcean NutraSciences Inc. (TSXV: BOC) in an interview with InvestorIntel’s CEO […]


Aloe Finance Inc.